Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Paradigm Biopharmaceuticals Ltd. (AU:PAR)
ASX:PAR
PAR Stock Chart & Stats
Day’s Range― - ―
52-Week RangeAU$0.17 - AU$0.61
Previous CloseN/A
Volume3.26M
Average Volume (3M)2.17M
Market Cap
$212.24M
Enterprise ValueAU$71.72M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.59
Next Earnings
Aug 29, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.19
Shares Outstanding389,428,600
10 Day Avg. Volume1,394,531
30 Day Avg. Volume2,165,902
Standard Deviation0.26
R-Squared0.13
Alpha-0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)6584.01
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.80Price Target Upside47.73% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Paradigm Biopharmaceuticals Ltd. News
PremiumCompany Announcements
Paradigm Biopharmaceuticals Director Acquires New Options
PremiumCompany Announcements
Paradigm Biopharmaceuticals Announces Director’s Securities Interest Update
PremiumCompany Announcements
Paradigm Biopharmaceuticals Amends Bonus Issue Announcement
PremiumCompany Announcements
Paradigm Biopharmaceuticals Announces Strategic Bonus Issue of Securities
PremiumCompany Announcements
Paradigm Biopharmaceuticals Announces ASX Quotation of Securities---
Options Prices
Currently, No data available
---
Ownership Overview
5.69% Insiders
<0.01% Other Institutional Investors
94.31% Public Companies and
Individual Investors
PAR FAQ
What was Paradigm Biopharmaceuticals Ltd.’s price range in the past 12 months?
Paradigm Biopharmaceuticals Ltd. lowest share price was AU$0.17 and its highest was AU$0.61 in the past 12 months.
What is Paradigm Biopharmaceuticals Ltd.’s market cap?
Paradigm Biopharmaceuticals Ltd.’s market cap is $212.24M.
When is Paradigm Biopharmaceuticals Ltd.’s upcoming earnings report date?
Paradigm Biopharmaceuticals Ltd.’s upcoming earnings report date is Aug 29, 2025 which is in 189 days.
How were Paradigm Biopharmaceuticals Ltd.’s earnings last quarter?
Currently, no data Available
Is Paradigm Biopharmaceuticals Ltd. overvalued?
According to Wall Street analysts Paradigm Biopharmaceuticals Ltd.’s price is currently Undervalued.
Does Paradigm Biopharmaceuticals Ltd. pay dividends?
Paradigm Biopharmaceuticals Ltd. does not currently pay dividends.
What is Paradigm Biopharmaceuticals Ltd.’s EPS estimate?
Paradigm Biopharmaceuticals Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Paradigm Biopharmaceuticals Ltd. have?
Paradigm Biopharmaceuticals Ltd. has 389,428,600 shares outstanding.
What happened to Paradigm Biopharmaceuticals Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Paradigm Biopharmaceuticals Ltd.?
Currently, no hedge funds are holding shares in AU:PAR
---
Paradigm Biopharmaceuticals Ltd. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$0.80 (47.73% Upside)
AU$0.80 (47.73% Upside)
Blogger Sentiment
Bullish
AU:PAR Sentiment 90%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $77.2K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
63.79%
12-Months-Change
Fundamentals
Return on Equity
-148.46%
Trailing 12-Months
Asset Growth
-59.03%
Trailing 12-Months
Company Description
Paradigm Biopharmaceuticals Ltd.
Paradigm Biopharmaceuticals Ltd is a biopharmaceutical company which engages in the research and development of therapeutic products for human use in Australia. The firm is engaged in drug repurposing, pentosan polysulphate sodium (PPS) for the lead clinical indication of bone marrow edema, Alphavirus - Ross River virus (RRV) and Chikungunya virus (CHIKV), Mucopolysaccharidosis, and allergic rhinitis.
---
PAR Stock 12 Month Forecast
Average Price Target
AU$0.80
▲(47.73% Upside)
Technical Analysis
Biotron Limited
―
Opthea Limited
―
CSL
―
Immutep Ltd
―
Medical Developments International Limited
―
Best Analysts Covering PAR
1 Year
1 Year Success Rate
0/7 ratings generated profit
1 Year Average Return
-34.73%
reiterated a buy rating 18 days ago
Copying John Hester's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -34.73% per trade.
---